HomeCompareGBS vs O

GBS vs O: Dividend Comparison 2026

GBS yields 422.65% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBS wins by $17170.28M in total portfolio value
10 years
GBS
GBS
● Live price
422.65%
Share price
$0.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17170.31M
Annual income
$11,716,925,996.02
Full GBS calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.18
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,098.20
Full O calculator →

Portfolio growth — GBS vs O

📍 GBS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGBSO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GBS + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GBS pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GBS
Annual income on $10K today (after 15% tax)
$35,925.61/yr
After 10yr DRIP, annual income (after tax)
$9,959,387,096.62/yr
O
Annual income on $10K today (after 15% tax)
$448.90/yr
After 10yr DRIP, annual income (after tax)
$4,333.47/yr
At 15% tax rate, GBS beats the other by $9,959,382,763.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GBS + O for your $10,000?

GBS: 50%O: 50%
100% O50/50100% GBS
Portfolio after 10yr
$8585.17M
Annual income
$5,858,465,547.11/yr
Blended yield
68.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

GBS
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-6.8
Piotroski
5/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.6% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GBS buys
0
O buys
0
No recent congressional trades found for GBS or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGBSO
Forward yield422.65%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$17170.31M$34.2K
Annual income after 10y$11,716,925,996.02$5,098.20
Total dividends collected$16675.91M$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: GBS vs O ($10,000, DRIP)

YearGBS PortfolioGBS Income/yrO PortfolioO Income/yrGap
1← crossover$52,965$42,265.43$10,818$607.86+$42.1KGBS
2$265,889$209,215.55$11,786$741.30+$254.1KGBS
3$1,266,062$981,561.13$12,944$910.50+$1.25MGBS
4$5,722,749$4,368,062.66$14,343$1,127.28+$5.71MGBS
5$24,575,825$18,452,483.99$16,053$1,408.17+$24.56MGBS
6$100,354,560$74,058,426.77$18,167$1,776.65+$100.34MGBS
7$390,010,320$282,630,940.68$20,815$2,266.60+$389.99MGBS
8$1,443,848,768$1,026,537,725.78$24,179$2,927.66+$1443.82MGBS
9$5,096,622,021$3,551,703,839.84$28,521$3,833.95+$5096.59MGBS
10$17,170,311,559$11,716,925,996.02$34,218$5,098.20+$17170.28MGBS

GBS vs O: Complete Analysis 2026

GBSStock

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Full GBS Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this GBS vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GBS vs SCHDGBS vs JEPIGBS vs KOGBS vs MAINGBS vs STAGGBS vs ADCGBS vs NNNGBS vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.